UK markets closed

DBV Technologies S.A. (DBVT)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
1.3901+0.0601 (+4.52%)
As of 11:54AM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Previous close1.3300
Open1.3400
Bid1.3900 x 1300
Ask1.4100 x 3100
Day's range1.3331 - 1.4000
52-week range1.1500 - 6.4700
Volume12,194
Avg. volume291,691
Market cap153.179M
Beta (5Y monthly)2.08
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • Globe Newswire

    Monthly information regarding the total number of voting rights and total number of shares of the Company as of April 30, 2022

    Monthly information regarding the total number of voting rights and total number of shares of the Company as of April 30, 2022 (Article 223-16 of the General Regulations of the Autorité des Marchés Financiers) Market : NYSE Euronext Paris ISIN Code: FR 0010417345 Date Total number of shares Total number of voting rights04/30/202255,095,537 Total gross of voting rights: 55,095,537 Total net* of voting rights: 54,920,329 * Total net = total number of voting rights attached to shares – shares witho

  • Globe Newswire

    DBV Technologies Announces Results of Its 2022 Ordinary and Extraordinary General Meeting

    Montrouge, France, May 12, 2022 DBV Technologies Announces Results of Its 2022 Ordinary and Extraordinary General Meeting Shareholders Approved All Proposed Resolutions DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today held its Ordinary and Extraordinary General Meeting. The General Meeting was chaired by Michel de Rosen, Chairman of DBV Technologies. The Company’s shareholders approved all resolutions submitted b

  • Globe Newswire

    DBV Technologies Completes ADSs Sale of an amount of $15.3 million on Nasdaq through its At-The-Market program (ATM)

    Montrouge, France, May 5, 2022 DBV Technologies Completes ADSs Sale of an amount of $15.3 million on Nasdaq through its At-The-Market program (ATM) DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Global Select Market: DBVT) (the “Company”), a clinical-stage biotechnological company, today announced that, pursuant to the Company’s At-The-Market program established on May 2, 2022 (the “ATM Program”), it has issued and completed sales of new ordinary shares (the “Ordinary Shares”) in